

Global Multiple Sclerosis Market: Trends and Opportunities (2013-18)



Scope of the Report

The report titled "Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)" provides an insight into the market dynamics and various trends and opportunities associated with the global multiple sclerosis market. The report analyzes the various causes and symptoms related to the prevalence of MS in patients. Further, the report analyzes the global market sizing and growth of multiple sclerosis in terms of revenue, number of patients and sales of effective drugs. Also, the domestic market of United States which is the largest contributor to the global multiple sclerosis market has been assessed. The report concludes with a brief discussion of major factors driving the global multiple sclerosis market and profiles major players like Teva, Biogen Idec, Merck KGaA, Bayer and Novartis.

Geographical Coverage

- Global
- United States

Company Coverage

- Teva
- Biogen Idec
- Merck KGaA
- Bayer
- Novartis

Executive Summary

The global Multiple Sclerosis market is undergoing drastic change since the last few years. The rising diagnosis and treatment rate coupled with growing investment in research and development has played a key role in the determining the growth dynamics of the global Multiple Sclerosis (MS) market.


Currently, MS is known to affect an estimated 2.5 million people around the world with around 5000 new cases emerging each year. Since there is no particular cure or treatment for multiple sclerosis, the market is currently dominated by few drugs and medication like Copaxone, Avonex, Betaseron and Extavia which delay or reduce the progression of multiple sclerosis in individuals.

Until the last year, MS market was led by self injectables drugs such as Capaxone and Avonex that caused side effects like swelling, anxiety, redness and difficult breathing. To address these shortcomings and side effects, pharmaceutical companies developed oral drugs that are considered safe and effective. With the beginning of 2013, oral drugs such as Gilenya and Aubagio witnessed rapid demand due to their higher efficacy and better results. In addition, there are many drugs down the pipeline that would change the dynamics and growth of the multiple sclerosis market in the future..


Global Multiple Sclerosis Market: An Overview

Multiple Sclerosis (MS) also known as disseminated sclerosis or encephalomyelitis disseminate is a chronic and often disabling disease that attacks nervous system, which comprises of brain, spinal cord and optic nerves. The global multiple sclerosis market has grown consistently over the past few years and is projected to maintain a positive momentum in the future as well.

Global Multiple Sclerosis Market Size, By Value, 2007-12 (US\$ Million)



Global Multiple Sclerosis Market Size Forecast, 2013-18 (US\$ Million)




- The Global multiple sclerosis market grew at CAGR of% during 2007-2012.
- The MS market is forecasted to grow at a CAGR of% during 2013-18, generating revenue of US\$..... billion in 2018.

Global Multiple Sclerosis Market

The global multiple sclerosis market is witnessing dramatic change over the last couple years. The market is highly technology and research oriented and very concentrated as the leading ten players dominate majority of the global market. The market is expected to witness the entry of new players and drugs in the coming future.

Global Multiple Sclerosis Market share, By Major Players, 2011



Teva's Copaxone and Biogen's Avonex are two of the leading drugs in the Multiple Sclerosis (MS) market with global share of% and% respectively in 2012.

Growth Drivers of Multiple Sclerosis Market

Changing Trend

-
-
-
-

Number of Eligible Patients

-
-
-
-
-

The Unmet Needs

-
-
-
-

Growing Healthcare Expenditure

-
-
-
-
-